What's New
Front Page
Landmark Trial Evaluating Potential FTD-GRN Therapeutic Completes Enrollment
Biotechnology company Alector Therapeutics announced on October 27 that it has completed enrollment for INFRONT-3, a Phase…
The Lived Experience of FTD: Anosognosia
The following article was written by Kevin Rhodes, a member of AFTD’s Persons with FTD Advisory Council….
AFTD Webinar: Grief, Loss, and Hope — Helping Families Living with FTD
FTD is the most common dementia for people under 60, and often occurs when there are teens…
Doctor Living with FTD Discusses Life Post-Diagnosis in Interview
In an interview recently broadcast by Atlanta News First, former gynecologist Dr. Seth Stern discussed his work…
Volunteer Update: Giving Purpose to the Pain – Becoming an AFTD Ambassador and FTD Advocate
AFTD Ambassadors know the power of a single story and the healing potential of finding others who…
Dear HelpLine: Long-Distance Care Partners
Dear HelpLine, My dad was recently diagnosed with FTD. I’m devastated by the diagnosis, but I live…
WebMD Staff Writer Shares His Experience as an ALLFTD Participant
WebMD staff writer Damian McNamara, MA, shared his experiences as an ALLFTD participant in a post published…
AviadoBio Begins Clinical Trial to Evaluate AVB-101 for Treatment of FTD
Today, AviadoBio announced the start of its Phase 1/2 clinical trial to evaluate AVB-101 as a one-time…
Advancing Hope: FTD Disorders Registry Deploying Upgraded Platform Under New Director
The FTD Disorders Registry is a powerful tool in the effort to discover treatments and a cure…
Case Report Co-Authored by AFTD Board Member Highlights Varying Presentations of FTD-GRN
A case report recently published in the journal Clinical Parkinsonism & Related Disorders highlights how even between…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)